Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 17, 2021

SELL
$14.61 - $22.19 $12.6 Million - $19.2 Million
-863,100 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$14.28 - $25.06 $472,668 - $829,486
33,100 Added 3.99%
863,100 $18.5 Million
Q3 2020

Nov 16, 2020

BUY
$10.5 - $17.6 $71,725 - $120,225
6,831 Added 0.83%
830,000 $12.6 Million
Q2 2020

Aug 14, 2020

BUY
$0.72 - $16.76 $592,681 - $13.8 Million
823,169 New
823,169 $10.3 Million

Others Institutions Holding LRMR

About Larimar Therapeutics, Inc.


  • Ticker LRMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,269,200
  • Market Cap $174M
  • Description
  • Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...
More about LRMR
Track This Portfolio

Track Acuta Capital Partners, LLC Portfolio

Follow Acuta Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acuta Capital Partners, LLC with notifications on news.